Search results
Showing 1851 to 1900 of 2046 results for work
Online help programme recommended for people with eating disorders
An online therapy programme can be used to help people aged 16 and over with eating disorders whilst they wait for specialist NHS treatment, an independent NICE has said.
Thousands living with lupus offered hope from twice-yearly infusion
NICE approves breakthrough combination treatment that restores normal kidney function in almost half of patients with lupus nephritis.
Digital platforms recommended to help people manage their asthma
People with asthma could benefit from digital tools on their phones or tablets to help them better manage their condition, states our draft guidance published today.
New sepsis guideline targets faster, tailored treatments to benefit patients
Patients aged 16 or over with suspected sepsis will receive more tailored treatment under updated NICE guidance published today.
NICE announces Professor Jonathan Benger as new Chief Executive
NICE Chairman, Sharmila Nebhrajani, today announced Professor Jonathan Benger CBE as incoming chief executive, with effect from Friday 19 December 2025 taking over from Dr Samantha Roberts.
NICE recommends new treatment option for highly active multiple sclerosis
Thousands of people living with a form of multiple sclerosis (MS) will benefit from greater treatment choice, following new guidance from NICE.
Dr Sam Roberts, chief executive at NICE, looks back at NICE's achievements over the past year and discusses our priorities for 2023.
Newly recommended CBT therapies could help children and young people deal with anxiety
NICE conditionally recommends digital cognitive behaviour therapies (CBT) for use in the NHS to help children and young people with symptoms of mild to moderate anxiety
Learn how NICE healthtech guidance helped East London NHS Foundation Trust tackle rising demand for children's mental health services.
Hundreds could benefit from life saving blood cancer treatment recommended by NICE
People with a rare and aggressive blood cancer will benefit from a potentially life saving treatment, following NICE’s recommendation of a CAR-T (chimeric antigen receptor T-cell) treatment developed by a British spinout company.
Fertility clinics must end unproven treatments that don't help couples have babies
Fertility clinics should not offer unproven treatments that do not help people have babies, our independent committee has recommended in draft guidance.
Accelerating innovation: How NICE is opening pathways to digital health technologies for the NHS
Following her appearance at this year’s HETT Show, programme director Sarah Byron tells us why the government’s 10 Year Plan is a game changer for healthtech and how we’re driving the changes at NICE.
New AI tools could help save lives by spotting warning signs of bowel cancer earlier
Five smart technologies that act as a "second pair of eyes" during bowel examinations have been conditionally recommended by NICE for NHS use, potentially helping doctors spot harmful growths that could turn into cancer.
For more than 25 years NICE has helped practitioners and commissioners get the best care to people, fast, while ensuring value for the taxpayer.
Preparing for the next breakthroughs in liver disease treatments
With no licensed treatments for MASH, a serious liver condition affecting 3 million in the UK, NICE has co-developed a framework with patients, clinicians, and industry to accelerate access to promising new medicines.
Learn about our role in the new international Health Economics Methods Advisory (HEMA) and its ambitions to make a real difference to patients around the world.
First HIV prevention injection for people unable to have daily PrEP recommended
A ground-breaking HIV-1 prevention injection has been recommended by NICE, marking a significant advance for a small group of adults and young people unable to have daily pre-exposure prophylaxis (PrEP) tablets.
Pre-exposure prophylaxis (PrEP) became routinely available through sexual health clinics in 2020, with NICE recommending the tablets for people at high risk of HIV in 2021.
Our chief executive, Dr Sam Roberts, welcomes the government's 10 Year Plan for healthcare
The government's 10 Year Plan marks a pivotal moment for healthcare and strengthens NICE’s role.
We explore the ongoing debate around NICE’s cost-effectiveness thresholds and what the future holds.
Same time decisions on licensing and value - what pharmaceutical companies need to know
Learn how NICE and MHRA are launching an aligned pathway to accelerate patient access to medicines and provide a more efficient route for industry.
NICE has been working in partnership with the London School of Economics and Political Science (LSE) to jointly develop and deliver an Executive MSc in Healthcare Decision-Making. Discover how this advanced healthcare training bridges clinical practice and system-wide decision-making through one committee member's transformative journey.
Hundreds of people set to benefit after life-extending lung cancer treatment given green light
Targeted immunotherapy found to significantly increase overall survival rates for people with an aggressive form of lung cancer has been recommended by NICE.
Breakthrough life-extending combination treatment for advanced bladder cancer recommended by NICE
The new treatment offers hope to thousands living with advanced urothelial cancer, with clinical trials showing overall survival rates were almost twice as long compared to standard treatment.
Biggest shake-up in type 2 diabetes care in a decade announced
Millions of people are set to benefit from earlier access to newer type 2 diabetes treatments – the biggest shake-up in care for a decade – as part of NICE’s commitment to re-evaluate priority clinical pathways described in the 10-Year Health Plan for the NHS.
People coming off obesity medication or finishing a weight management programme should be offered support to help keep the weight off and stay healthy long-term, according to our updated quality standard.
Patients to receive medicines 3 to 6 months faster under 10-Year Health Plan
NICE and the Medicines and Healthcare products Regulatory Agency (MHRA) have described how the 10-Year Health Plan will lead to faster medicines access for patients in the NHS in England.
Final decision on cerliponase alfa for Batten disease treatment confirmed
In final draft guidance published today we've confirmed that we’re unable to recommend cerliponase alfa (also called Brineura and made by BioMarin) for routine NHS use in treating neuronal ceroid lipofuscinosis type 2 (CLN2), a rare and life-limiting form of Batten disease.
Hundreds with rare inherited eye disease to benefit after NICE recommends treatment
NICE recommends idebenone for Leber's hereditary optic neuropathy following clinical evidence of vision improvement.
After four years of transformational leadership, NICE CEO Dr Sam Roberts will step down at the end of the year to support her children through a difficult time.
Some people with cystic fibrosis are set to benefit from a new once-daily triple therapy treatment, following NICE's recommendation of Alyftrek in final draft guidance published today.
How NICE International is supporting evidence-based decision-making through the Regulatory Partnership for Growth Fund
Thousands could benefit from first immunotherapy for severe birch tree pollen allergy
We have recommended the first under-the-tongue tablet immunotherapy shown to build long-term tolerance to allergens, which could help up to 27,000 people in England with moderate to severe birch tree pollen allergies.
NICE responds to publication of the government's Life Sciences Sector Plan
We welcome the publication of the government's Life Sciences Sector Plan, which sets out how NICE will ensure patients get faster, fairer access to transformative new medicines and life-changing healthtech, while supporting a thriving life sciences industry in the UK.
Thousands more breast cancer patients to benefit from new NHS treatment
NICE approves ribociclib combination therapy to help prevent cancer returning in early-stage disease.
The innovative hybrid closed loop (HCL) systems offer improved blood sugar control and can transform daily life for families managing this complex condition.
NICE leads the way in approving breakthrough treatment for multiple myeloma
People in England will become the first in the world to receive belantamab mafodotin for this indication following our recommendation and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) approval earlier this year.
Over 4,200 people set to benefit after we recommend daily pill to treat rare chronic kidney disease
New treatment sparsentan has been found to slow down the progression of kidney damage, which will change people’s lives for the better.
Up to 1,000 women a year could benefit from new at-home treatment for endometriosis
Today we've recommended a new treatment option for symptoms of endometriosis that can be taken at home.
New weekly treatment option approved for people with haemophilia B
Our final draft guidance published today recommends marstacimab (also called Hympavzi and made by Pfizer) for treating the severe form of blood disorder haemophilia B in people 12 years and over.
Health inequalities - an update to NICE's methods for health technology evaluation
Our new modular update focuses on how we consider health inequalities when evaluating technologies for use in the NHS, and how you can get involved in suggesting future updates.
AI skin cancer detection system gets green light for conditional NHS use
An artificial intelligence system for potential skin cancer has been conditionally recommended for use in the NHS for the next three years while further evidence is collected.
NICE recommends Piqray and Trodelvy, maintaining 100% approvals of breast cancer drugs since 2018.
NICE recommends Enhertu for more people with advanced breast cancer
Hundreds more people eligible for breast cancer drug Enhertu as NICE recommends it for earlier stage disease, in final draft guidance.
NICE chronic lung disease treatment decision could benefit 5,200 people
NICE broadens nintedanib recommendation on chronic lung disease treatment.
Improvements for people with acute kidney injury in updated quality standard
An updated quality standard published today (23 March 2023) by NICE outlines improvements in care for people who have or are at risk of acute kidney injury.
NICE recommends life-changing gene therapy for children with ultra-rare genetic disorder
The first and currently only gene therapy for children with an ultra-rare genetic disorder has been recommended by NICE.
Dr Sam Roberts has been outlining the changes underway at NICE to meet the challenges of a rapidly evolving health technology sector and patient expectations
Decision aid to guide discussions on sleeping pill prescriptions
A patient decision aid on medicines associated with dependence or withdrawal symptoms has been published
NICE recommends 8 digitally enabled therapies to treat depression and anxiety
Eight digital enabled therapies to treat depression and anxiety disorders in adults have been conditionally recommended by NICE in draft guidance.